Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Crinetics Pharmaceuticals Inc Market Cap
From what 3 stock analysts predict, the share price for Crinetics Pharmaceuticals Inc (CRNX) might increase by 32.44% in the next year. This is based on a 12-month average estimation for CRNX. Price targets go from $48 to $97. The majority of stock analysts believe CRNX is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
About 3 Wall Street analysts have assigned CRNX 2 buy ratings, 1 hold ratings, and 0 sell ratings. This means that analysts expect Crinetics Pharmaceuticals Inc to outperform the market. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on CRNX. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of CRNX.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Jonathan Wolleben JMP Securities | Market Outperform | $80 | Reiterates | Sep 27, 2024 |
| Josh Schimmer Cantor Fitzgerald | Overweight | $90 | Reiterates | Sep 16, 2024 |
| Leland Gershell Oppenheimer | Outperform | $73 | Reiterates | Aug 9, 2024 |
| Douglas Tsao HC Wainwright & Co. | Buy | $69 | Maintains | Aug 9, 2024 |
| Jessica Fye JP Morgan | Overweight | $54 | Maintains | Jul 9, 2024 |
| Yasmeen Rahimi Piper Sandler | Overweight | $97 | Maintains | Jul 2, 2024 |
| Douglas Tsao HC Wainwright & Co. | Buy | $60 | Reiterates | Jun 28, 2024 |
| Leland Gershell Oppenheimer | Outperform | $74 | Maintains | Jun 4, 2024 |
| Jonathan Wolleben JMP Securities | Market Outperform | $80 | Reiterates | Jun 4, 2024 |
| Douglas Tsao HC Wainwright & Co. | Buy | $60 | Reiterates | Jun 4, 2024 |
| Brian Skorney Baird | Outperform | $62 | Maintains | May 23, 2024 |
| Douglas Tsao HC Wainwright & Co. | Buy | $60 | Reiterates | May 23, 2024 |
| Jeffrey Hung Morgan Stanley | Overweight | $70 | Maintains | May 23, 2024 |
| Josh Schimmer Cantor Fitzgerald | Overweight | $65 | Reiterates | May 14, 2024 |
| Jonathan Wolleben JMP Securities | Market Outperform | $80 | Reiterates | May 10, 2024 |
| Douglas Tsao HC Wainwright & Co. | Buy | $60 | Reiterates | May 10, 2024 |
| Yasmeen Rahimi Piper Sandler | Overweight | $97 | Maintains | May 7, 2024 |
| Jonathan Wolleben JMP Securities | Market Outperform | $80 | Reiterates | Mar 28, 2024 |
| Jonathan Wolleben JMP Securities | Market Outperform | $80 | Maintains | Mar 20, 2024 |
| Lina Kaminski JonesTrading | Buy | $56 | Maintains | Mar 20, 2024 |
When did it IPO
2018
Staff Count
290
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Dr. R. Scott Struthers Ph.D.
Market Cap
$4.25B
In 2023, CRNX generated $4.0M in revenue, which was a decrease of -15.28% from the previous year. This can be seen as a signal that CRNX's business is declining, and its share price could be worth less in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Thu, 26 Sep 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Crinetics Pharmaceuticals submitted an NDA to the FDA for paltusotine, a once-daily oral treatment for acromegaly, marking a significant step in its development.
Why It Matters - Crinetics' NDA submission for paltusotine could lead to FDA approval, potentially increasing revenue and market share in the acromegaly treatment sector, positively impacting stock value.
Tue, 10 Sep 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Crinetics Pharmaceuticals granted non-qualified stock options for 120,200 shares to 15 new non-executive employees as part of its 2021 Inducement Plan on September 10, 2024.
Why It Matters - The granting of stock options to new employees can signal confidence in company growth and attract talent, potentially impacting future performance and stock value positively.
Thu, 29 Aug 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Crinetics Pharmaceuticals (Nasdaq: CRNX) will participate in fireside chats at the Morgan Stanley and Cantor Global Healthcare Conferences in September 2024, focusing on endocrine therapeutics.
Why It Matters - Crinetics Pharmaceuticals' participation in major healthcare conferences signals potential interest and investment in its developments, impacting investor sentiment and stock performance.
Mon, 12 Aug 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Crinetics Pharmaceuticals granted 103,900 stock options to 15 new non-executive employees on August 10, 2024, under its 2021 Employment Inducement Plan, per Nasdaq rules.
Why It Matters - Stock options granted to new employees can motivate talent and align their interests with shareholders, potentially enhancing company performance and stock value.
Thu, 08 Aug 2024
Sentiment - NEUTRAL
Source - Seeking Alpha
Summary - Crinetics Pharmaceuticals will hold its Q2 2024 earnings conference call on August 8, 2024, at 4:30 PM ET, featuring key executives and analysts from major financial firms.
Why It Matters - Crinetics Pharmaceuticals' Q2 2024 results may reveal financial health and strategic direction, impacting stock performance and investor confidence in the company's future prospects.
Thu, 08 Aug 2024
Sentiment - NEGATIVE
Source - Zacks Investment Research
Summary - Crinetics Pharmaceuticals (CRNX) reported a quarterly loss of $0.94 per share, worse than the Zacks Consensus Estimate of $0.86, matching last year's loss.
Why It Matters - Crinetics Pharmaceuticals' larger-than-expected loss signals potential financial instability, which may lead to decreased investor confidence and affect stock performance.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
